In response to ROS signaling in the TME, the released gemcitabine reduced the percentage of immunosuppressive cells, including MDSCs and M2 macrophages, while increasing PD-L1 expression in cancer cells, T cells, macrophages, and DCs. This evidence concerns the gene CD274 and cancer.